We are live on ! Find out more
ADVM

Adverum Biotechnologies

Delisted

ADVM was delisted on the 8th of December, 2025.

96 hedge funds and large institutions have $255M invested in Adverum Biotechnologies in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 14 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

257% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 14

116% more call options, than puts

Call options by funds: $22.3M | Put options by funds: $10.3M

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

15% less funds holding

Funds holding: 11396 (-17)

45% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 38

60% less capital invested

Capital invested by funds: $642M → $255M (-$387M)

Holders
96
Holders Change
-17
Holders Change %
-15.04%
% of All Funds
2.59%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
21
Increased
50
Reduced
14
Closed
38
Calls
$22.3M
Puts
$10.3M
Net Calls
+$12M
Net Calls Change
+$2.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$62.1M +$5.2M +15,416 +4%
VM
2
VHCP Management
New York
$22.5M
CCM
3
Cadian Capital Management
New York
$16.4M +$22.8M +67,500 +202%
Millennium Management
4
Millennium Management
New York
$16M +$29.7M +88,052 +844%
BFA
5
BlackRock Fund Advisors
California
$13.6M +$10.4M +30,760 +58%
FCM
6
Frontier Capital Management
Massachusetts
$13M +$17.4M +51,577 +181%
JP Morgan Chase
7
JP Morgan Chase
New York
$10.4M -$680K -2,014 -3%
RG
8
Redmile Group
California
$8.72M +$3.92M +11,615 +28%
Vanguard Group
9
Vanguard Group
Pennsylvania
$8.57M +$2.02M +5,993 +13%
Invesco
10
Invesco
Georgia
$6.35M +$11.5K +34 +0.1%
LCM
11
Laurion Capital Management
New York
$6.1M +$12.7M +37,554 New
Balyasny Asset Management
12
Balyasny Asset Management
Illinois
$5.11M +$10.6M +31,464 New
BIT
13
BlackRock Institutional Trust
California
$4.81M +$2.64M +7,836 +36%
NI
14
Numeric Investors
Massachusetts
$4.17M +$8.67M +25,710 New
WCM
15
Wildcat Capital Management
New York
$3.82M +$7.94M +23,526 New
Goldman Sachs
16
Goldman Sachs
New York
$3.59M +$7.47M +22,130 New
State Street
17
State Street
Massachusetts
$3.41M +$3.66M +10,850 +107%
SM
18
Sabby Management
Florida
$3.21M +$4.82M +14,286 +260%
Axa
19
Axa
France
$3.19M +$1.47M +4,354 +29%
RPAM
20
Rhenman & Partners Asset Management
Sweden
$2.5M +$3.75M +11,101 +258%
Group One Trading
21
Group One Trading
Illinois
$2.34M +$3.78M +11,189 +345%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$1.87M -$1.12M -3,328 -22%
Northern Trust
23
Northern Trust
Illinois
$1.66M +$660K +1,957 +24%
ARTA
24
A.R.T. Advisors
New York
$1.63M +$3.38M +10,027 New
TCIM
25
TIAA CREF Investment Management
New York
$1.31M +$1.83M +5,412 +205%

ADVM Hedge Fund Activity: Q2 2015 in Review

96 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2015, worth a combined $255M — down 60% from $642M a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of ADVM and 21 opened new positions — a net loss of 17 holders — while 14 trimmed existing stakes and 50 added.

The largest buyer was Millennium Management, adding an estimated $29.7M. The largest seller was Deerfield Management, exiting entirely with an estimated $85.8M sold.

  • 96 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2015, down from 113 in Q1 2015.
  • Funds reported $255M of Adverum Biotechnologies stock for Q2 2015, down 60% quarter-over-quarter.
  • 21 funds opened new Adverum Biotechnologies positions in Q2 2015 and 38 closed out, a net change of -17 holders.
  • The largest Adverum Biotechnologies buyer in Q2 2015 was Millennium Management, an estimated $29.7M added.
  • The largest Adverum Biotechnologies seller in Q2 2015 was Deerfield Management, an estimated $85.8M sold.

Based on aggregated 13F filings for Q2 2015.